Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling
暂无分享,去创建一个
M. Asselin-Labat | Daniel P Steinfort | S. Bozinovski | V. Gayevskiy | T. Leong | Lesley-Ann Gray | Hao Wang | C. Aloe | Savreet Aujla
[1] C. Gridelli,et al. Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy , 2022, International journal of molecular sciences.
[2] S. Hendry,et al. PD-L1 copy number loss in NSCLC associates with reduced PD-L1 tumour staining and a cold immunophenotype. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] A. Stenzinger,et al. Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] A. Marchetti,et al. Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record , 2020, Cancers.
[5] Y. Shimizu,et al. Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer. , 2019, Journal of thoracic disease.
[6] C. Escriu,et al. Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response , 2019, Lung cancer.
[7] S. Fröhling,et al. Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: separating biology from technical artifacts. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] Pham Nguyen Quy,et al. Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay. , 2019, The oncologist.
[9] Mingchao Xie,et al. TMB standardization by alignment to reference standards: Phase II of the Friends of Cancer Research TMB Harmonization Project. , 2019, Journal of Clinical Oncology.
[10] E. Valtorta,et al. The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience , 2019, BioMed research international.
[11] P. Russell,et al. Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer , 2018, Oncogene.
[12] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[13] E. Jaffee,et al. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.
[14] P. Galante,et al. A straightforward assay to evaluate DNA integrity and optimize next-generation sequencing for clinical diagnosis in oncology. , 2017, Experimental and molecular pathology.
[15] E. Jaffee,et al. Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.
[16] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.